Addiction Technology Transfer Center Network. (2023) Understanding Xylazine: an emerging concern. Addiction Technology Transfer Center Network.
Preview | Title | Contact |
---|---|---|
|
PDF (Understanding Xylazine: an emerging concern)
- Published Version
683kB |
Xylazine (or “tranq”) is a non-opioid sedative and tranquilizer only approved for use in veterinary medicine. However, over the past several years, human consumption of xylazine has begun rapidly increasing. Although initially only identified in illicit drug supplies in limited areas, xylazine has been found in 48 states as of April 2023. Xylazine is frequently, though not exclusively, used in conjunction with opioids, particularly fentanyl—due to xylazine’s ability to prolong their effects. Xylazine use presents many potential dangers to people, including an increased risk of overdose and the development of necrotizing tissue damage. This factsheet details key concerns, overdose responses, harm reduction techniques, and more.
G Health and disease > Substance use disorder (addiction) > Drug use disorder > Drug intoxication > Poisoning (overdose)
G Health and disease > Substance use disorder (addiction) > Drug use disorder > Drug withdrawal / craving
G Health and disease > Cardiovascular / heart disease
J Health care, prevention, harm reduction and treatment > Harm reduction > Substance use harm reduction
J Health care, prevention, harm reduction and treatment > Identification and screening > Identification and screening for substance use
VA Geographic area > International
Repository Staff Only: item control page